21 CFR Part 11 Compliance for Electronic Records and Signatures

Companies want to transition to electronic records but are afraid of compromising their quality system and receiving 483’s at their next inspection. Part of this fear originates from confusion. FDA originally published a rather severe 21 CFR Part 11. After industry complaints the FDA acknowledged that the regulation, as written, would result in nobody attempting to convert to electronic records. But, instead of rewriting the regulation, FDA said it would “selectively enforce” sections of the regulation. This webinar will explain what all this means. The confusion over the original FDA regulation and its subsequent “selective enforcement” will be explained.

Why You Should Attend:

This Webinar will explain what 21 CFR Part 11 is, why it is important to FDA regulated companies and how conformance to Part 11 differs from just having good IT security. Procedures for controlling electronic signatures and electronic records will be explained.

FDA regulated companies want to transition to electronic records for economy and efficiency. FDA, because of its concern for patient safety, wants to prevent electronic records from being compromised with possible resulting harm to the patient.

FDA has set up regulations that address both data security and patient safety. We will show how 21 CFR part 11 considers both.

You will also receive a 21 CFR checklist and a Test protocol form as handouts.

Areas Covered In The Session:

• Origin of the regulation and changes in Interpretation
• Electronic Records
• Electronic Signatures
• Data Security
• Open, closed and hybrid Systems
• Validation Methods
• Risk Analysis

Who Should Attend:

• Quality Assurance Departments
• Regulatory Affairs Departments
• Engineering Departments
• IT Departments
• Validation Departments
• Documentation Departments

Course Director: EDWIN WALDBUSSER

Edwin Waldbusser retired from industry after 30 years in management of development of medical device products and development of company Quality Systems. He was involved in the development of products such as IVD devices, kidney dialysis systems and inhalation devices. His QS experience includes, design control, risk analysis, CAPA, software validation, supplier qualification/ control and manufacturing/non-conforming product programs. He now consults in the area of quality systems for medical devices with emphasis on design control, software validation, risk analysis and human factors analysis. Ed has a B.S. Mechanical Engineering from NYU and a M.B.A from Drexel University. He is certified by Lloyds of London as an ISO 9000 Lead Auditor and is a member of the Thomson Reuters Expert Witness network. He has 5 issued patents.